Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 1/20 | 0.76 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.76 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.76 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.76 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.71 |
| ▸ | NCOA3 | Q9Y6Q9 | 2/20 | 0.71 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.71 |
| ▸ | NPC1 | O15118 | 2/20 | 0.68 |
| ▸ | RAB9A | P51151 | 1/20 | 0.68 |
| ▸ | MEN1 | O00255 | 4/20 | 0.64 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.61 |
| ▸ | GPR55 | Q9Y2T6 | 2/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12008965 | 0.96 | KMT2A (0.78) | CASP3SENP8SENP7SENP6KMT2A | |
| SCHEMBL13446915 | 0.91 | CASP3 (0.63) | CASP3SENP8SENP7SENP6KMT2A | |
| SCHEMBL12008972 | 0.83 | PKM (0.73) | SENP8SENP7SENP6KMT2ANPC1 | |
| SCHEMBL12008911 | 0.81 | FFAR1 (0.70) | KMT2ANPC1RAB9AMEN1FFAR1 | |
| SCHEMBL13446906 | 0.80 | POLB (0.73) | KMT2ANPC1RAB9AMEN1FFAR1 | |
| SCHEMBL12008893 | 0.80 | KMT2A (0.65) | KMT2ANPC1MEN1FFAR1GPR55 | |
| SCHEMBL12008863 | 0.80 | KMT2A (0.74) | KMT2ANPC1MEN1FFAR1GPR55 | |
| SCHEMBL12008871 | 0.79 | KMT2A (0.81) | SENP8SENP7SENP6KMT2AMEN1 | |
| SCHEMBL15428382 | 0.79 | NCOA3 (0.92) | CASP3SENP8SENP7SENP6KMT2A | |
| SCHEMBL12006896 | 0.77 | FFAR1 (1.00) | KMT2ANPC1RAB9AMEN1FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170049751-A1 | OXAZOLE AND THIAZOLE COMPOUNDS AS BETA-CATENIN MODULATORS AND USES THEREOF | DASGUPTA RAMANUJ (US) | 2017-02-23 | — | — | US | disclosed |
| US-20170049751-A1 | OXAZOLE AND THIAZOLE COMPOUNDS AS BETA-CATENIN MODULATORS AND USES THEREOF | DASGUPTA RAMANUJ (US) | 2017-02-23 | — | — | US | disclosed |
| US-9433611-B2 | Oxazole and thiazole compounds as β-catenin modulators and uses thereof | NEW YORK UNIVERSITY (US) | 2016-09-06 | — | — | US | disclosed |
| US-9433611-B2 | Oxazole and thiazole compounds as β-catenin modulators and uses thereof | NEW YORK UNIVERSITY (US) | 2016-09-06 | — | — | US | disclosed |
| US-20130109675-A1 | OXAZOLE AND THIAZOLE COMPOUNDS AS BETA-CATENIN MODULATORS AND USES THEREOF | NEW YORK UNIVERSITY | 2013-05-02 | — | — | US | disclosed |
| US-20130109675-A1 | OXAZOLE AND THIAZOLE COMPOUNDS AS BETA-CATENIN MODULATORS AND USES THEREOF | NEW YORK UNIVERSITY | 2013-05-02 | — | — | US | disclosed |
| US-8252823-B2 | Oxazole and thiazole compounds as beta-catenin modulators and uses thereof | NEW YORK UNIVERSITY (US) | 2012-08-28 | — | — | US | disclosed |
| US-8252823-B2 | Oxazole and thiazole compounds as beta-catenin modulators and uses thereof | NEW YORK UNIVERSITY (US) | 2012-08-28 | — | — | US | disclosed |
| US-20090227624-A1 | Oxazole and thiazole compounds as beta-catenin modulators and uses thereof | US ARMY, SECRETARY OF THE ARMY | 2009-09-10 | — | — | US | disclosed |
| US-20090227624-A1 | Oxazole and thiazole compounds as beta-catenin modulators and uses thereof | US ARMY, SECRETARY OF THE ARMY | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227624-A1 | Oxazole and thiazole compounds as beta-catenin modulators and uses thereof | CTNNB1, CTNNA1, CTNNBL1 | CASP3 1807/4885SENP8 4665/4885SENP7 4576/4885 |
| US-20170049751-A1 | OXAZOLE AND THIAZOLE COMPOUNDS AS BETA-CATENIN MODULATORS AND USES THEREOF | CTNNB1, CTNNA1, CTNNBL1 | CASP3 1807/4885SENP8 4665/4885SENP7 4576/4885 |
| US-20130109675-A1 | OXAZOLE AND THIAZOLE COMPOUNDS AS BETA-CATENIN MODULATORS AND USES THEREOF | CTNNB1, CTNNA1, CTNNBL1 | CASP3 1807/4885SENP8 4665/4885SENP7 4576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.